B16-F10 Syngeneic Model Overview
The B16-F10 syngeneic model is one of the most widely utilized and well-characterized murine models of malignant melanoma, derived from a spontaneous melanoma in C57BL/6 mice. It represents an aggressive, poorly immunogenic tumor system frequently used for investigating melanoma biology, metastatic dissemination, and preclinical immunotherapy. The B16-F10 line is a clonal derivative of the parental B16 melanoma, selected for its high metastatic potential following serial in vivo passage through the lungs.
When implanted subcutaneously or intravenously, B16-F10 cells generate reproducible tumors with consistent growth kinetics and characteristic pigmentation due to melanin production. The model has become a standard for testing immune checkpoint blockade, cytokine-based therapies, and adoptive T-cell strategies in an immunocompetent C57BL/6 background. Its high metastatic activity and defined growth behavior make B16-F10 an indispensable platform for assessing both local tumor control and systemic anti-tumor immunity.
Request a Custom Quote for B16F10 Syngeneic ModelBiological and Molecular Characteristics
The B16-F10 cell line was established from a spontaneous melanoma in C57BL/6 mice and is a subclone of the parental B16 line, enriched for metastatic competency. B16-F10 tumors exhibit spindle-shaped, pigmented melanoma cells with high mitotic activity and limited immune recognition. The line is characterized by low MHC class I expression, which contributes to immune evasion, and by elevated production of angiogenic and immunosuppressive cytokines such as VEGF, IL-10, and TGF-β.
Despite its relatively low intrinsic immunogenicity, the B16-F10 model is frequently used to evaluate strategies that restore immune visibility, enhance antigen presentation, or promote cytotoxic T-cell activation. The tumor microenvironment is dominated by suppressive myeloid cells and regulatory T cells, making it a challenging but translationally relevant system for testing immune-modulating therapies.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Spontaneous melanoma (mouse) |
| Histological type | Poorly differentiated melanoma |
| Inoculation route | Subcutaneous, intravenous, or intradermal |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | High; lung metastases frequent after IV injection |
| Immunophenotype | Low MHC I expression, macrophage- and Treg-rich microenvironment |
| Common applications | Immunotherapy, metastasis, cytokine and checkpoint inhibitor studies |
In Vivo Model Development and Tumorigenicity
The B16-F10 model is typically established by subcutaneous implantation of tumor cells into immunocompetent C57BL/6 mice, resulting in rapid and uniform tumor development within 4–6 days post-inoculation. Intravenous injection of tumor cells produces widespread pulmonary metastases, enabling precise quantification of metastatic colonization and anti-metastatic therapeutic efficacy. Intradermal implantation may also be used to model cutaneous melanoma progression and local immune infiltration.
Primary B16-F10 tumors grow aggressively and reach measurable size rapidly, facilitating short-duration efficacy studies. The model’s consistent growth kinetics, combined with its high metastatic propensity, make it particularly useful for comparing local versus systemic immune responses. Because of its poor intrinsic immunogenicity, B16-F10 serves as a benchmark system for developing therapies aimed at overcoming immune tolerance and promoting robust T-cell activation against melanoma antigens.
Request a Custom Quote for B16F10 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of B16-F10 tumors reveals dense sheets of spindle-shaped, melanin-producing cells with hyperchromatic nuclei and minimal glandular organization. Tumor sections often contain regions of necrosis surrounded by proliferating cells, reflecting high metabolic demand and rapid turnover. The stroma is sparsely cellular and contains infiltrating macrophages and lymphocytes concentrated at the tumor margins.
Immunohistochemical analysis shows moderate Ki-67 expression consistent with active proliferation and extensive melanin deposition within tumor cells. CD3 and CD8 staining identify T-cell presence at the peritumoral interface, while F4/80 and CD11b staining highlight macrophage and myeloid-derived suppressor cell infiltration. PD-L1 expression is detectable on both tumor and infiltrating immune cells, with upregulation observed following interferon stimulation. The histological and immunohistochemical features of B16-F10 tumors closely resemble those of poorly differentiated, immune-evasive melanoma, making the model highly suitable for translational research in immuno-oncology.
Preclinical Applications and Drug Response
The B16-F10 syngeneic model is a cornerstone of immunotherapy research due to its aggressive biology, metastatic behavior, and immune resistance, which closely mirror advanced human melanoma. It has been extensively used to evaluate immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, as well as cytokine-based and adoptive cell therapies. Anti–PD-1 and anti–CTLA-4 monotherapies yield modest responses in this model, reflecting its low immunogenicity, while combination regimens significantly improve survival and immune activation.
B16-F10 is also employed in preclinical testing of tumor vaccines, oncolytic viruses, and agents designed to modulate macrophage polarization and Treg suppression. Combination therapies involving checkpoint blockade and cytokine therapy (e.g., IL-2 or IL-12) have shown potent synergy, resulting in increased T-cell infiltration and durable tumor regression in a subset of animals. The model’s reproducibility and aggressive growth pattern make it ideal for evaluating the balance between immune stimulation, tumor escape, and therapeutic durability.
Request This Model
To request the B16-F10 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for B16F10 Syngeneic Model